Aranesp dose regimens simplified

Dialysis patients with chronic renal failure receiving Aranesp (darbepoetin alfa) in the maintenance phase of treatment for anaemia may now be treated on alternate weeks instead of weekly.

Dialysis patients converting from a once-weekly to a once-every-other-week Aranesp regimen should initially receive a dose equivalent to twice the previous once-weekly dose.

Furthermore, clinical studies have demonstrated that patients receiving recombinant human erythropoietin once, twice or three times per week may be converted to a once-weekly or a once-every-other-week regimen of Aranesp. In such cases, the initial weekly dose of Aranesp in microgram per week, can be determined by dividing the total weekly dose of recombinant human erythropoietin in IU/week by 200. Similarly, the initial alternate weekly dose of Aranesp in microgram every other week, can be determined by dividing the total dose of recombinant human erythropoietin in IU over a two-week period by 200.

In all patients, haemoglobin should be monitored every one or two weeks and subsequent dosing titrated individually as necessary to maintain the haemoglobin target.

Further information: Amgen Ltd, 240 Cambridge Science Park, Milton Road, Cambridge CB2 4LX. Tel: (01223) 420305.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more